Skip to content
GCC AI Research

Search

Results for "Pharmaceuticals"

A shape-shifting approach to industrial design

KAUST ·

KAUST researchers are exploring novel chemical reactors and separation processes using mathematical design, with a focus on time and shape variables to enhance transport, heat transfer, and mass transfer. By aligning design, modeling, and 3D printing, they create customized shapes with great complexity and less material. This approach allows for the creation of bespoke reactors and separation processes tailored to specific applications, improving efficiency and reducing energy consumption. Why it matters: This research demonstrates the potential of advanced manufacturing techniques to revolutionize industrial design in the Middle East's chemical and pharmaceutical sectors.

KAUST agreement targets pressing healthcare issues, bolsters biotech and pharma sector

KAUST ·

KAUST signed an MoU with MISA and Novo Nordisk at the Riyadh Global Medical Biotechnology Summit 2023. The agreement aims to address healthcare challenges in Saudi Arabia and develop the biotech and pharma sector through knowledge transfer and research. A key objective is to establish a Novo Nordisk Center of Excellence focused on obesity and metabolic research. Why it matters: The partnership will boost Saudi Arabia's Vision 2030 goals of creating tech-driven industries and improving health outcomes through biotechnology.

Ph.D. student's innovative research wins awards

KAUST ·

KAUST Ph.D. student Khalil Moussi won two awards at the IEEE International Conference on Nano/Micro Engineered and Molecular Systems for his research on a miniaturized drug delivery system. The system, developed in collaboration with KAIMRC, uses 3D printing and wireless power to deliver drugs for coronary artery disease treatment. The device features an electrochemical micro-pump, a 3D printed reservoir with microneedles, and a wireless powering unit, allowing customization for various in vivo drug delivery applications. Why it matters: This recognition highlights KAUST's contributions to biomedical engineering and its potential to develop innovative solutions for critical healthcare challenges in the region and beyond.

New smart-drug research may help target cancer therapy

KAUST ·

KAUST researchers led by Dr. Niveen Khashab have developed thermosensitive liposomes for controlled drug release, particularly in cancer therapies. The liposomes are designed to release drugs only when they reach heated tumor tissue, minimizing systemic side effects. Cholesterol moieties are used as anchors to create a "nail" or "comb" effect, enabling temperature-triggered drug release inside cells. Why it matters: This targeted drug delivery system could significantly improve the efficacy and reduce the toxicity of cancer treatments.

Disrupting The Drug Development Process Using Multi-Modal Deep Learning and Patient-on-a-Chip Platform

MBZUAI ·

Shahar Harel, Head of AI at Quris, presented a BIO-AI approach to drug safety assessment using a 'patient-on-a-chip' platform. This platform simulates the human body and generates high-frequency microscopy and biochemical data on drug interactions, considering patient genomics and ethnicity. The data is used to train multimodal deep learning models to predict drug safety and provide patient-specific recommendations. Why it matters: This approach offers a potential alternative to animal models, promising faster and more personalized drug development while reducing safety concerns.

Agreement signed for building of The Saudi Vaccine and Biomanufacturing Center (SVBC)

KAUST ·

The Research Products Development Company (RPDC) signed an agreement with The Saudi Vaccine and Biomanufacturing Center (SVBC) to establish a research and industrial center in Saudi Arabia for vaccine and biopharmaceutical development. Supported by KACST and hosted by KAUST, the SVBC will provide a state-of-the-art facility and a training platform. Cooperation agreements were also signed with GE for equipment supply and with Fujifilm Dayosent Biotechnology for MERS-CoV treatment development. Why it matters: This initiative aims to localize vaccine and advanced treatment industries in Saudi Arabia, create technical jobs, and reduce reliance on imports in line with Vision 2030.

How corals reveal the ocean’s hidden chemical footprint

KAUST ·

Researchers from King Abdullah University of Science and Technology (KAUST) conducted a study revealing that Red Sea corals absorb and accumulate various compounds, including pharmaceuticals, personal care products, and herbicides, thereby recording a long-term chemical footprint of human activity. The study detected substances like antibiotics, anti-inflammatories, and the herbicide atrazine across 15 reefs in three Red Sea regions, noting that some chemicals were found in higher concentrations offshore due to ocean currents. This research demonstrates how corals can provide a more comprehensive, time-integrated picture of environmental exposure than water samples alone. Why it matters: This work offers a valuable tool for environmental monitoring and informing policy in Saudi Arabia as it expands coastal tourism and other sectors, particularly for the unique Red Sea coral reef ecosystems.

KAUST healthcare collaborations usher era of precision personalized medicine

KAUST ·

The KAUST Smart-Health Initiative (KSHI) held its annual forum, showcasing research collaborations with partners like KFSHRC, KAIMRC, and KACST. Projects presented included biomarker detection devices, cardiovascular disease sensors, 3D data visualization, and genome sequencing for patient data analysis. Dr. Sara F. Althari highlighted KAUST's cultivation of partnerships within the Kingdom's healthcare and biotech ecosystem. Why it matters: The KSHI aims to transform Saudi Arabia's healthcare system towards precision and personalized medicine, aligning with Vision 2030.